Literature DB >> 16083971

Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate.

David Azoulay1, Veronika Vachapova, Boris Shihman, Ariel Miler, Arnon Karni.   

Abstract

Neuronal growth factors may exert a neuroprotective effect in multiple sclerosis (MS). We found reduced levels of brain-derived neurotrophic factors (BDNF) in the serum and CSF of relapsing-remitting MS patients, which was reversed by therapy with glatiramer acetate. BDNF may play a protective role in MS, and immunomodulation therapy, such as with glatiramer acetate, may enhance the action this mechanism.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16083971     DOI： 10.1016/j.jneuroim.2005.07.001

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN： 0165-5728            Impact factor:   3.478


  51 in total

1.  Decreased serum BDNF levels in patients with epileptic and psychogenic nonepileptic seizures.

Authors:  W C LaFrance; K Leaver; E G Stopa; G D Papandonatos; A S Blum
Journal:  Neurology       Date:  2010-10-05       Impact factor: 9.910

Review 2.  Neuroplasticity - exercise-induced response of peripheral brain-derived neurotrophic factor: a systematic review of experimental studies in human subjects.

Authors:  Kristel Knaepen; Maaike Goekint; Elsa Marie Heyman; Romain Meeusen
Journal:  Sports Med       Date:  2010-09-01       Impact factor: 11.136

3.  Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.

Authors:  Aaron Boster; Mary Pat Bartoszek; Colleen O'Connell; David Pitt; Michael Racke
Journal:  Ther Adv Neurol Disord       Date:  2011-09       Impact factor: 6.570

4.  The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice.

Authors:  Rina Aharoni; Raya Eilam; Hagit Domev; Galya Labunskay; Michael Sela; Ruth Arnon
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

5.  Aerobic fitness is associated with gray matter volume and white matter integrity in multiple sclerosis.

Authors:  Ruchika Shaurya Prakash; Erin M Snook; Robert W Motl; Arthur F Kramer
Journal:  Brain Res       Date:  2009-06-25       Impact factor: 3.252

Review 6.  Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases.

Authors:  Nabil K El Ayoubi; Samia J Khoury
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

7.  Lower brain-derived neurotrophic factor levels associated with worsening fatigue in prostate cancer patients during repeated stress from radiation therapy.

Authors:  L N Saligan; N Lukkahatai; G Holder; B Walitt; R Machado-Vieira
Journal:  World J Biol Psychiatry       Date:  2015-03-27       Impact factor: 4.132

8.  Control of extracellular cleavage of ProBDNF by high frequency neuronal activity.

Authors:  Guhan Nagappan; Eugene Zaitsev; Vladimir V Senatorov; Jianmin Yang; Barbara L Hempstead; Bai Lu
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-15       Impact factor: 11.205

Review 9.  Neurogenesis and neuroprotection in the CNS--fundamental elements in the effect of Glatiramer acetate on treatment of autoimmune neurological disorders.

Authors:  Ruth Arnon; Rina Aharoni
Journal:  Mol Neurobiol       Date:  2007-10-11       Impact factor: 5.590

10.  The impact of regular physical activity on fatigue, depression and quality of life in persons with multiple sclerosis.

Authors:  Nicole M Stroud; Clare L Minahan
Journal:  Health Qual Life Outcomes       Date:  2009-07-20       Impact factor: 3.186
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.